You are here

IPF

Galapagos spotlights an ‘exciting’ round of PoC data for IPF drug, shares surge

Endpoints

Thu, 08/10/17 - 11:53 am

EC clears Boehringer Ingelheim's Ofev for idiopathic pulmonary fibrosis

First Word Pharma

Mon, 01/19/15 - 12:02 pm

Boehringer Ingelheim

idiopathic pulmonary fibrosis

Bristol-Myers beefs up fibrosis pipeline with $444M option deal

Fierce Biotech

Mon, 11/3/14 - 09:28 am

Bristol-Myers Squibb

Galecto Biotech

idiopathic pulmonary fibrosis

Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF

Fierce Pharma Marketing

Thu, 10/23/14 - 08:41 am

Boehringer Ingelheim

Roche, Boehringer Drugs Wins Approval for Lung Disease

Bloomberg

Wed, 10/15/14 - 04:49 pm

Boehringer Ingelheim

idiopathic pulmonary fibros

The 3 Biggest Biotech Wins of the Week

Motley Fool

Wed, 05/28/14 - 10:52 am

Gilead Sciences

Factor XI inhibitor

Isis Pharmaceuticals

InterMune Gains After Lung Disease Drug Slows Damage

Bloomberg

Mon, 05/19/14 - 09:36 am

idiopathic pulmonary fibrosis

Biotech Stock Mailbag: Previewing InterMune's Big Week Ahead

TheStreet.com

Fri, 05/16/14 - 10:07 am

idiopathic pulmonary fibrosis

Boehringer Ingelheim

InterMune Hits Home Run With Pivotal Lung Drug Study Results

TheStreet.com

Tue, 02/25/14 - 08:14 am

idiopathic pulmonary fibrosis

Rejection of InterMune’s Drug Told Early to FDA Advisers

Bloomberg

Wed, 12/26/12 - 09:23 am

InterMune Gearing Up For Another Round With The FDA

Yahoo/Reuters

Thu, 11/29/12 - 12:03 pm

idiopathic pulmonary fibrosis

InterMune's Esbriet rings up $2.8 million in sales since mid-September launch in Germany

Yahoo/AP

Thu, 01/5/12 - 01:01 pm

idiopathic pulmonary fibrosis

InterMune Surges on EC Drug Approval

Barron's

Thu, 03/3/11 - 05:57 pm

5 Drugmakers Headed Back to the Drawing Board

Motley Fool

Mon, 01/31/11 - 06:54 pm

Arena Pharmaceuticals

InterMune to start new IPF drug trial

Bizjournals

Mon, 01/10/11 - 12:37 pm

Gilead ends trial of lung disease drug candidate

Yahoo/AP

Thu, 12/23/10 - 08:34 am

Gilead Sciences

idiopathic pulmonary fibrosis

Gilead to Buy Arresto Biosciences for $225 Million to Obtain Lung Medicine

Bloomberg

Mon, 12/20/10 - 12:29 pm

Arresto Biosciences

Gilead Sciences

idiopathic pulmonary fibrosis

FibroGen: Drug could reduce lung fibrosis

Bizjournals.com

Tue, 05/18/10 - 09:54 am

InterMune Batting .500

Motley Fool

Tue, 02/3/09 - 03:30 pm

InterMune Investors Eager for Lung-Drug Data

TheStreet.com

Mon, 01/26/09 - 11:38 am

Pages